Epidemiology and patient journey in inclusion body myositis: A machine learning methodology applied to claims data in the United States
AAN 2025 Poster

Pharmacokinetics, pharmacodynamics, and safety profile of ulviprubart: Results from a 48-week, open-label, phase 1 study in patients with inclusion body myositis
AAN 2025 Poster

Selective Depletion of KLRG1⁺ T cells in a First-in-Human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM), GCOM 2022 Poster

Goel et al., Depletion of KLRG1⁺ T cells in a First-in-Human Clinical Trial of ABC008 in Inclusion Body Myositis (IBM), ACR 2021 Poster

Greenberg et al., Highly differentiated cytotoxic T cells in inclusion body myositis, Brain 2019 Sep 1;142(9):2590-2604

Greenberg, Inclusion body myositis: clinical features and pathogenesis, Nat Rev Rheumatol, 2019 May;15(5):257-272

Greenberg et al., Association of inclusion body myositis with T cell large granular lymphocytic leukaemia, Brain 2016 May;139(Pt 5):1348-60